Healthcare
Oncolytics Biotech Inc.(ONCY)
Live Price
Offline$0.96
+3.23% today
1Y Change
+39.13%
Window
Jun 25, 2025 โ Jun 18, 2026
- Market Cap
- $120.00M
- Revenue Growth
- 0.0%
- EPS Growth
- +26.8%
- Dividend Yield
- 0.0%
Coverage: 247 bars ยท Jun 25, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Oncolytics Biotech Inc. (ONCY) is a Healthcare stock with a market cap of $120.00M and listed on NASDAQ. The stock last traded around $0.96 and up 39.1% across the available one-year price window (Jun 25, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +26.8%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +26.8%, free cash flow +26.1% with operating margin 0.0% and ROIC -1715.9%. Stock Foundry combines ONCY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 13, 2026, but the surprise data is still limited.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is +26.8%, while operating margin sits near 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -1.1% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 13, 2026 | โ | +0.0% | -5.7% | -5.7% |
2026 Mar 30, 2026 | -33.3% | +4.9% | +11.1% | +11.1% |
2025 Nov 12, 2025 | +16.7% | -5.3% | -8.8% | -12.3% |
Benchmark Edge
ONCY vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
ONCY
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
ONCY Max Drawdown
-45.07%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for ONCY and SPY.
Company Overview
Oncolytics Biotech Inc.
NASDAQ Capital Market
Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC. The company was incorporated in 1998 and is headquartered in Calgary, Canada.
- Leadership
- Jared Kelly
- IPO Date
- Oct 5, 2001
- Employees
- 28
- Street Address
- 322 11th Avenue SW
- Mailing
- Calgary, AB, T2R 0C5
- Region
- Calgary, AB, CA
- Reporting Currency
- USD
- Investor Line
- 14036707380
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- โ
Growth
- Revenue
- 0.0%
- EPS
- +26.8%
- Free Cash Flow
- +26.1%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -1292.7%
- ROIC
- -1715.9%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 1.12
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.